ODN D-SL03

Name: ODN D-SL03
SKU: CGON-19
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CGON-19

Inquire for Price

Product Information

Cat. No.	CGON-19
Description	CpG oligodeoxynucleotides (or CpG ODNs) are synthetic oligonucleotides that contain unmethylated CpG motifs. CpG ODN can bind to and activate a Toll-like receptor 9 (TLR9) and leading to strong immunostimulatory effects. So far 3 major classes of CpG ODNs have been identified, based on their structural and biological characteristics, and are designated Type A, Type B, and Type C. Type A ODNs, which feature a central palindromic CpG-containing phosphodiester (PO) structure followed by a phosphorothioate (PS) homopolymeric G-stretch, are robust inducers of interferon-α (IFN-α) production and dendritic cell maturation. Type B ODNs, in contrast, contain a full phosphorothioate backbone with one or more CpG dinucleotides. They strongly activate B cells but stimulate weakly IFN-α secretion. Type C ODNs, combine the properties of both Type A and B, and are characterized by their complete PS backbone and palindromic CpG-containing motifs. Type C ODNs induce strong IFN-α production from pDC and B cell stimulation. ODN D-SL03 is a type C CpG ODN specific for multispecies TLR9.
Features	• Classification: Type C • Product format: Lyophilized product • Sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' (lower case letters are phosphorothioate) • Specificity: Multispecies
Storage	Store lyophilized product at -20°C. Upon reconstitution, aliquots should be stored at -20°C and are stable for 6 months. Avoid repeated freeze-thaw cycles.

Quick Inquiry

Q & A

Customer Reviews

Customer Q&As

What is the sequence of ODN D-SL03?

A: The sequence of ODN D-SL03 is 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'.

What is the function of ODN D-SL03?

A: ODN D-SL03 can activate human B cells, NK cells, and monocytes, upregulating the expression of CD80, CD86, and HLA-DR on human PBMC subpopulations. ODN D-SL03 can also inhibit tumor growth.

What is the concentration and exposure time for in vitro research experiments using ODN D-SL03?

A: ODN D-SL03 (0-3 μg/mL; 36 h) significantly induces IFN-α production at 0.19 μg/mL in PBMCs. ODN D-SL03 (3 μg/mL; 18 or 36 h) activates immune cells, including B, NK, T, and monocytes.

What is the dosage for in vivo studies using ODN D-SL03 in mice?

A: ODN D-SL03 (25 μg per mouse, intraperitoneal injection) results in significant inhibition of tumor growth.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *